Exclusive Collaboration and Licensing Agreement

In December 2016, Conatus announced an exclusive option, collaboration and license agreement with Novartis for the global development and commercialization of emricasan. In May 2017, Conatus announced that Novartis had exercised its license option.

Multiple parallel clinical trials, the EmricasaN, a Caspase inhibitOR, for Evaluation, or ENCORE trials, evaluated a range of emricasan doses over various treatment durations in patients of different etiologies.

Licensing Opportunities

If you are interested in licensing assets to or from Conatus for further development, please contact us.